Table IV.
Association between the distribution of LAPTM4B genotypes and clinicopathological parameters in DLBCL cases.
| LAPTM4B genotypes | ||||
|---|---|---|---|---|
| Parameters | *1/1 | *1/2 | *2/2 | P-valuea |
| Sex | ||||
| Male | 43 | 31 | 7 | 0.64 |
| Female | 44 | 33 | 4 | |
| Age | ||||
| ≤50 | 46 | 29 | 4 | 0.456 |
| >50 | 41 | 35 | 7 | |
| B symptomsb | ||||
| Positive | 36 | 21 | 5 | 0.494 |
| Negative | 51 | 43 | 6 | |
| LDH | ||||
| Positive | 45 | 37 | 4 | 0.392 |
| Negative | 42 | 27 | 7 | |
| β2-MG | ||||
| Positive | 23 | 19 | 5 | 0.532 |
| Negative | 58 | 42 | 6 | |
| Stage | ||||
| I–II | 40 | 31 | 4 | 0.757 |
| III–IV | 47 | 33 | 7 | |
| Bulky mass | ||||
| ≥10 cm | 9 | 7 | 2 | 0.766 |
| <10 cm | 78 | 57 | 9 | |
| Localized | ||||
| Yes | 13 | 10 | 2 | 0.961 |
| No | 74 | 54 | 9 | |
| No extra nodalc | ||||
| ≤1 | 68 | 46 | 7 | 0.474 |
| >1 | 19 | 18 | 4 | |
| Incidence site | ||||
| Lymph node | 50 | 36 | 6 | 0.977 |
| Extra lymph | 37 | 28 | 5 | |
| IPI score | ||||
| 0–2 | 66 | 43 | 5 | 0.102 |
| 3–5 | 21 | 21 | 6 | |
| Molecular subtypes | ||||
| GCB | 12 | 16 | 0 | 0.102 |
| Non-GCB | 61 | 41 | 9 | |
| Other | 14 | 7 | 2 | |
a
Analyzed using χ2 test or Fisher's exact test.
b
B symptom includes unexplained fever/chills/weight loss, fatigue and drenching night sweats.
c
No extra nodal: the number and type of extra nodal will influence DLBCL patient prognosis. LAPTM4B, lysosomal protein transmembrane 4β; DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; MG, macroglobulin; IPI, International Prognostic Index; GCB, germinal center B cell.